Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(6):479–485. doi: 10.1111/j.1349-7006.2003.tb01469.x

Molecular mechanisms of angiogenesis in non‐small cell lung cancer, and therapeutics targeting related molecules

Seiji Yano 1, Yasuhiko Nishioka 1, Hisatsugu Goto 1, Saburo Sone 1,✉
PMCID: PMC11160313  PMID: 12824870

Abstract

Angiogenesis, neovascularization from pre‐existing vasculature, is necessary to supply oxygen and nutrition for tumor growth in both primary and distant organs. It consists of sprouting and non‐sprouting (the enlargement, splitting, and fusion of pre‐existing vessels) processes, and both can occur concurrently. Growth of solid tumors, including non‐small cell lung cancer (NSCLC), is usually dependent on angiogenesis, which is regulated by complex mechanisms involving various angiogenesis‐related molecules. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), one of the most potent angiogenic molecules, regulates both angiogenesis and vascular permeability, and hence promotes tumor progression and development of malignant pleural effusions in NSCLC. Signals via epidermal growth factor receptor (EGFR) promote not only the tumor cell cycle, but also the process of angiogenesis. Therefore, these molecules are potential targets for anti‐tumor vasculature therapy. Many agents targeting tumor vasculature have been developed, and several compounds have shown anti‐tumor potential in pre‐clinical studies. Their efficacy against NSCLC is currently being evaluated in clinical trials.

References

  • 1. Ries LAG, Eisner MP, Kosary CL. SEER cancer statistics review, 19731998) Bethesda , MD : National Cancer Institute; 2001) [Google Scholar]
  • 2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 6 Suppl 16: 15–8. [DOI] [PubMed] [Google Scholar]
  • 3. Scappaticci FA. Mechanisms and future directions for angiogenesis‐based cancer therapies. J Clin Oncol 2002; 20: 3906–27. [DOI] [PubMed] [Google Scholar]
  • 4. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671–4. [DOI] [PubMed] [Google Scholar]
  • 5. Herbst RS, Fidler IJ. Angiogenesis and lung cancer: potential for therapy. Clin Cancer Res 2000; 6: 4604–6. [PubMed] [Google Scholar]
  • 6. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. Expression of vascular endothelial growth factor is essential but not sufficient for production and growth of brain metastasis. Cancer Res 2000; 60: 4959–67. [PubMed] [Google Scholar]
  • 7. Fidler IJ, Yano S, Zhang R, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularization and brain metastases. Lancet Oncol 2002; 3: 53–7. [DOI] [PubMed] [Google Scholar]
  • 8. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter KC, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M, Rilke F. Non‐small‐cell lung carcinoma tumor growth without morphological evidence of neo‐angiogenesis. Am J Pathol 1997; 151: 1417–23. [PMC free article] [PubMed] [Google Scholar]
  • 9. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA, Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non‐small‐cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 881–6. [DOI] [PubMed] [Google Scholar]
  • 10. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H. Evaluation of angiogenesis in non‐small cell lung cancer: comparison between anti‐CD34 antibody and anti‐CD 105 antibody. Clin Cancer Res 2001; 7: 3410–5. [PubMed] [Google Scholar]
  • 11. Meert AP, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout JM, Lafitte JJ, Mascaux C, Sculier JP. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta‐analysis. Br J Cancer 2002; 87: 694–701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G. Vascular endothelial growth factor is associated with neovascularization and influences progression of non‐small cell lung carcinoma. Clin Cancer Res 1997; 3: 861–5. [PubMed] [Google Scholar]
  • 13. Brown PD, Bloxidge RE, Stuart NSE, Gatter KC, Carmichale J. Association between expression of activated 72‐kilodalton gelatinase and tumor spread in non‐small‐cell lung carcinoma. J Natl Cancer Inst 1993; 85: 574–8. [DOI] [PubMed] [Google Scholar]
  • 14. Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G, Ciardiello F. Evaluation of epidermal growth factor‐related growth factors and receptors and of neoangiogenesis in completely resected stage I‐IIIA non‐small‐cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998; 4: 241–9. [PubMed] [Google Scholar]
  • 15. Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, Otake Y, Wada H. Expression of angiopoietins and its clinical significance in non‐small cell lung cancer. Cancer Res 2002; 62: 7124–9. [PubMed] [Google Scholar]
  • 16. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Comley M, Whitehouse RM, Talbot DC, Gatter KC, Harris AL. Platelet‐derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non‐small‐cell lung cancer. Br J Cancer 1997; 75: 477–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5: 1001–5. [PubMed] [Google Scholar]
  • 18. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368–80. [DOI] [PubMed] [Google Scholar]
  • 19. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC, Lee YC. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non‐small‐cell lung cancer. J Clin Oncol 2001; 19: 432–41. [DOI] [PubMed] [Google Scholar]
  • 20. Yano S, Nishioka Y, Izumi K, Tsuruo T, Tanaka M, Miyasaka M, Sone S. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int J Cancer 1996; 67: 211–7. [DOI] [PubMed] [Google Scholar]
  • 21. Yano S, Nokihara H, Hanibuchi M, Parajuli P, Shinohara T, Kawano T, Sone S. Model of malignant pleural effusion of human lung adenocarcinoma in SCID mice. Oncol Res 1997; 9: 573–9. [PubMed] [Google Scholar]
  • 22. Miki T, Yano S, Hanibuchi M, Sone S. Bone metastasis model with multior‐gan dissemination of human small‐cell lung cancer (SBC‐5) cells in natural killer cell‐depleted SCID mice. Oncol Res 2000; 12: 209–17. [DOI] [PubMed] [Google Scholar]
  • 23. Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 1999; 48: 396–400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/ vascular permeability factor by human lung cancer cells. Am J Pathol 2000; 157: 1893–903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Plate KH. From angiogenesis to lymphangiogenesis. Nat Med 2001; 7: 151–2. [DOI] [PubMed] [Google Scholar]
  • 26. Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y, Oda M, Sasaki T, Watanabe G. The expression of vascular endothelial growth factor C and its receptors in non‐small cell lung cancer. Br J Cancer 2001; 85: 255–60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 2003; 97: 457–64. [DOI] [PubMed] [Google Scholar]
  • 28. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178–93. [DOI] [PubMed] [Google Scholar]
  • 29. Passlick B, Sienel W, Seen‐Hibler R, Wockel W, Thetter O, Mutschler W, Pantel K. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early‐stage non‐small cell lung cancer. Clin Cancer Res 2000; 6: 3944–8. [PubMed] [Google Scholar]
  • 30. Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Differential expression of E‐cadherin and type IV collagenase genes predicts outcome in patients with stage I non‐small cell lung carcinoma. Clin Cancer Res 2000; 6: 790–7. [PubMed] [Google Scholar]
  • 31. Shiraga M, Yano S, Yamamoto A, Ogawa H, Goto H, Miki T, Miki K, Zhang H, Sone S. Organ heterogeneity of host‐derived matrix metalloproteinase expression and its involvement in multiple‐organ metastasis by lung cancer cell lines. Cancer Res 2002; 62: 5967–73. [PubMed] [Google Scholar]
  • 32. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000; 77: 25–79. [PubMed] [Google Scholar]
  • 33. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor‐associated endothelial cells for therapy of androgen‐independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003; 9: 1200–10. [PubMed] [Google Scholar]
  • 34. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554–60. [PubMed] [Google Scholar]
  • 35. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, Paesmans M, Steels E, Verdebout JM, Sculier JP. The role of EGF‐R expression on patient survival in lung cancer: a systematic review with meta‐analy‐sis. EurRespirJ 2002; 20: 975–81. [DOI] [PubMed] [Google Scholar]
  • 36. Kanematsu T, Yano S, Uehara H, Bando Y, Sone S. Phosphorylation, but not Overexpression of epidermal growth factor receptor is associated with poor prognosis of non‐small cell lung cancer patients. Oncol Res 2003; in press. [DOI] [PubMed]
  • 37. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–6. [DOI] [PubMed] [Google Scholar]
  • 38. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002; 6 Suppl 16: 3–9. [DOI] [PubMed] [Google Scholar]
  • 39. Yano S, Herbst RS, Shinohara S, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000; 6: 957–65. [PubMed] [Google Scholar]
  • 40. Johnson DH, DeVore R, Kabbinavar F, Herbst RS, Holmgren E, Novotny W. Carboplatin (C)+Paclitaxel (T)+RhuMab‐VEGF (AVF) may prolong survival in advanced non‐squamous lung cancer. Proc Am Soc Clin Oncol 2001; 20: 1256a. [Google Scholar]
  • 41. Langmuir VK, Cobleigh MA, Herbst RS, Holmgren E, Hurwitz H, Kabbinavar F, Miller K, Novotny W. Successful long‐term therapy with bev‐acizumab (Avastin) in solid tumors. Proc Am- Soc Clin Oncol 2002; 21: 32a. [Google Scholar]
  • 42. Yamamoto A, Yano S, Shiraga M, Ogawa H, Goto H, Miki T, Zhang H, Sone S. A third generation matrix metalloproteinase (MMP) inhibitor (ONO‐4817) combined with docetaxel suppresses progression of lung‐microme‐tastasis of MMP expressing tumor cells in nude mice. Int J Cancer 2003; 103: 822–8. [DOI] [PubMed] [Google Scholar]
  • 43. Fielding J, Scholefield J, Stuart R, Hawkins R, McCulloch P, Maughan T, Seymour M, Van Cutsem E, Thorlacius‐Ussing O, Hovendal C. A randomized double‐blind placebo‐controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc Am Soc Clin Oncol 2000; 19: 929a. [Google Scholar]
  • 44. Shepherd FA, Giaccone G, Debruyne C, Hirsh V, Smylie M, Rubin S, Martins H, Lamont A, Krzakowski M, Zee B, Sadura A, Seymour L. Randomized double‐blind placebo‐controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first‐line chemotherapy: an NCIC‐CTG and EORTC study. Proc Am Soc Clin Oncol 2001; 20: 11a. [DOI] [PubMed] [Google Scholar]
  • 45. Smylie M, Mercier R, Aboulafia D, Tucker R, Bonomi P, Collier M, Rose Keller M, Stuart‐Smith J, Knowles M, Clendeninn NJ, Shepherd F. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non‐small cell lung cancer (NSCLC). Proc Am Soc Clin On.col 2001; 20: 1926a. [Google Scholar]
  • 46. Randal J. Antiangiogenesis drugs target specific cancers, mechanisms. J Natl Cancer Inst 2000; 92: 520–2. [DOI] [PubMed] [Google Scholar]
  • 47. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002; 8: 1974–83. [PubMed] [Google Scholar]
  • 48. Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S. Activity of a new vascular targeting agent, ZD6126 in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 2002; 62: 3711–5. [PubMed] [Google Scholar]
  • 49. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G. The microtubule‐affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843–9. [PubMed] [Google Scholar]
  • 50. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 Suppl 4: 2–8. [DOI] [PubMed] [Google Scholar]
  • 51. Negoro S, Nakagawa K, Fukuoka M, Kudoh S, Tamura T, Yoshimura N, Takeda K, Tanigawara Y, Swaisland H. Final results of a phase I intermittent dose‐escalation trial of ZD1839 (‘Iressa’) in Japanese patients with various solid tumors. Proc Am. Soc Clin Oncol 2001; 20: 324; 1292a. [Google Scholar]
  • 52. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste JF, Kudo S, Averbuch S, Macleod A Feyereis‐lova A, Baselga J. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non‐small‐cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21: 298a. [DOI] [PubMed] [Google Scholar]
  • 53. Barkley JE, Green MR. Bronchioloalveolar carcinoma. J Clin Oncol 1996; 14: 2377–86. [DOI] [PubMed] [Google Scholar]
  • 54. Yano S, Kanematsu T, Miki T, Aono S, Azuma M, Yamamoto A, Uehara H, Sone S. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’). Cancer Sci 2003; 94: 453–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Giaccone G, Johnson DH, Manegold C, Scagliotti GV. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemo‐naive patients with advanced non‐small cell lung cancer (INTACT 1). Ann Oncol 2002; 13 Suppl 5: 2–3. [Google Scholar]
  • 56. Johnson DH, Herbst RS, Giaccone G, Schiller J. ZD1839 (Iressa) in combination with paclitaxel and Carboplatin in chemotherapy‐naive patients with advanced non‐small cell lung cancer; results from a phase III clinical trial (INTACT 2). Ann Oncol 2002; 13 Suppl 5: 127–8. 12401678 [Google Scholar]
  • 57. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Severe acute interstitial pneumonia and ge‐fitinib. Lancet 2003; 361: 137–9. [DOI] [PubMed] [Google Scholar]
  • 58. Kerbel RS. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 2001; 19 Suppl 18: 45S–51S. [PubMed] [Google Scholar]
  • 59. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002; 20: 3804–14. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES